Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $27.34. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| ACAD | FNGU | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $36.15 |
52-Week Low | $20.06 | $13.73 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FNGU is a leveraged exchange-traded note tracking the FANG+ Index, currently trading at $27.39, up 3.4% over the past day. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and short-term RSI suggests caution. Recent news highlights extreme volatility, with a 16% single-session drop reported on June 5, 2026, underscoring the risks of its 3x leverage structure.
The outlook for FNGU is highly speculative, offering amplified exposure to major tech stocks but carrying significant decay and volatility risks. Investment opportunity exists for aggressive traders betting on sustained tech sector strength, while the primary risk is rapid capital erosion during market downturns or flat periods, as evidenced by recent performance gaps versus the underlying index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
